Indrayani Biotech Limited has announced receiving official listing approval from the BSE Limited for 83,64,036 equity shares. These shares, each with a face value of Rs. 10/-, were issued as part of a rights issue. The approval, dated November 06, 2026, grants permission for the listing and trading of these shares on the exchange, marking a significant step in the company’s capital-raising efforts.
BSE Approves Listing of Rights Issue Shares
Indrayani Biotech Limited has officially secured listing approval from the BSE Limited for a substantial issuance of equity shares. The approval pertains to 83,64,036 equity shares, each with a face value of Rs. 10/-, which were issued through a recent rights issue. The company received the formal listing approval on November 06, 2026.
Details of the Rights Issue
This approval allows for the subsequent listing and trading of these equity shares on the exchange. The rights issue was conducted in accordance with the applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has been informed by BSE that trading will commence after confirmation from the Depositories regarding the credit of shares to beneficiary accounts.
Regulatory Compliance
Indrayani Biotech is reminded that it must submit an application for trading approval to the stock exchange(s) within seven working days from the date of grant of listing approval, as per SEBI circulars. Failure to comply may attract fines.
Source: BSE
